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Abstract (196 words/200)  
The “one-off” approach of systematic reviews is no longer sustainable; we need to 
move toward producing “living” evidence syntheses (i.e., comprehensive, based on rigorous 
methods, and up-to-date). This implies rethinking the evidence synthesis ecosystem, its 
infrastructure and management. The three distinct production systems — primary research, 
evidence synthesis and guidelines development — should work together to allow for 
continuous refreshing of synthesized evidence and guidelines. A new evidence ecosystem, 
not just focusing on synthesis, should allow for bridging the gaps between evidence synthesis 
communities, primary researchers, guidelines developers, health technology assessment 
agencies, and health policy authorities. This network of evidence synthesis stakeholders 
should select relevant clinical questions considered a priority topic. For each question, a 
multi-disciplinary community including researchers, health professionals, guidelines 
developers, policymakers, patients and methodologists needs to be established and commit to 
performing the initial evidence synthesis and keeping it up to date. Encouraging communities 
to work together continuously with bidirectional interactions requires greater incentives, 
rewards and the involvement of healthcare policy authorities to optimize resources. A better 
evidence ecosystem with collaborations and interactions between each partner of the network 
of evidence synthesis stakeholders should permit living evidence syntheses to justify their 
status in evidence-informed decision-making. 
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What is new? 
 
▪ Reinforcing the link between trialists and systematic reviewers is a major objective to 
implement a virtuous circle of continuous improvement in the quality of evidence, in 
primary research and therefore in future evidence synthesis. 
▪ Our expectations regarding the synthesis of evidence need to be rethought by 
considering a synthesis as a product in a process of continuous extension and 
improvement rather than a finished product valid at a single time. 
▪ Implementing living network meta-analyses and living clinical practice guidelines 
will help in outlining what is not known, allow for assessing the trustworthiness of the 
evidence and help the research community streamline future clinical trials and focus 




An accurate, concise, up-to-date and unbiased synthesis of available evidence is arguably one 
of the most valuable contributions a research community can offer patients, healthcare 
providers, guideline developers, funders, health policy-makers or health systems managers 
and other decision-makers [1]. Changes in healthcare research, advancements in technology 
and the development of new methods are converging in new ways to produce higher-quality 
evidence synthesis (i.e., based on more rigorous methods and a timely, comprehensive search) 
for better healthcare decision-making. However, these developments imply rethinking the 
evidence synthesis ecosystem, its infrastructure and management and to move toward an 
evidence ecosystem.  
For clinical research, we can no longer afford the “one-off” approach of systematic 
reviews relying on repeated construction and deconstruction of ephemeral review teams in a 
“staccato” fashion [2]. A system based on multiple initiatives arising from uncoordinated 
groups of researchers working to answer narrow questions focusing on only some of the 
various treatments of interest at one point in time is questionable. Such a state is frequently 
inefficient, wastes time and resources and leads to a fragmented global picture of evidence 
(Future of evidence ecosystem series: 1. Introduction — Evidence synthesis ecosystem needs 
dramatic change; this issue). We need to move toward producing “living” evidence syntheses 
— comprehensive, based on rigorous methods, up-to-date evidence syntheses, and updated as 
new research becomes available [3]. Better coordination is needed to identify enduring 
questions and allocate them globally. For each topic, a large, multi-disciplinary research 
community is needed to undertake the effort and commit to maintaining an up-to-date 
synthesis over time.  
Crucially, there is also a need to bridge the gap between the evidence synthesis 
community and trialists who are positioned at the beginning of completed trials being 
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synthesized and future trials being planned and conducted. Currently, there are three distinct 
production systems that largely function in parallel and without any systematic integration: 
primary research (i.e., clinical studies and other research studies), evidence synthesis and 
guidelines development. However, these production systems are actually highly 
interdependent, but such interdependency is limited to data and not organisation. They all 
contribute to the overall evidence production system. To accelerate the pace of production of 
relevant evidence, improve the efficiency of this system and facilitate translation into practice, 
a global community of communities bridging cultures, countries and scientific disciplines 
needs to be built. This community would be a large-scale, global, learning health system that 
can continuously and routinely improve itself.  
 
1. RETHINKING EVIDENCE SYNTHESIS 
1.1 Encouraging communities to work together and co-create to allow for continuous 
refreshing of synthesized evidence 
High-quality evidence synthesis is a public good [1] that needs to be permanently refreshed to 
be up-to-date and useful. Such an updating process, which is increasingly becoming 
cumbersome and complex, requires the involvement of many researchers. Greater incentives 
and rewards are needed to promote the enormous effort required to produce a high-quality 
systematic review and for updating over time. Furthermore, these communities would be 
engaged in a process of co-creation in which input from consumers but also other decision 
makers will play a central role from beginning to end.  
1.2 Rethinking the link between primary research and future evidence synthesis 
The link between primary evidence and evidence synthesis could be viewed differently. To 
adequately plan their trials, trialists should be aware that results of only a very few trials 
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definitively change practice. Findings from most trials help build evidence by being integrated 
in a systematic review. For example, estimates from systematic reviews are used to inform 
sample size calculation; knowledge gained in previous trials such as recruitment, retention, 
and outcome measurement is used to help plan and conduct new trials efficiently. 
Furthermore, results of initial trials published in high-impact journals are frequently 
contradicted or the benefits are less strong that initially suggested [4]. Trialists must anticipate 
that the results of their trials will be integrated later in a systematic review and meta-analysis. 
Therefore, in addition to ensuring that their study sample size can adequately adress the 
question being posed, they should also compute the trial sample size to be able to potentially 
change meta-analysis results and record all important outcomes even if they are belived to be 
not informative at the trial level (e.g., safety) [5,6]. Furthermore, creation of standards for 
reporting data could allow to bypass the data extraction process and include the data straight 
from primary producers to synthesize. 
1.3 Optimizing the trade-off between speed and thoroughness  
Evidence synthesis is an evolving field of research. Over time, the complexity and rigor of 
methods used in reviews have increased considerably. The mechanisms established for 
producing high-quality up-to-date systematic reviews are resource-intensive, and timely 
generation of the reviews is challenging. Dealing with multiple sources of data (Future of 
evidence ecosystem series: 2. Current opportunities and need for better tools and methods; 
this issue) further compounds the work of systematic reviewers. The delay from the decision 
to perform a review to its completion is increasing. However, all stakeholders (clinicians, 
researchers, policymakers) are making daily decisions and need syntheses of evidence that 
could inform these decisions. The increased complexity of the methods and quality checks 




A good-enough version (of evidence synthesis) available before making a decision is 
much more valuable than a perfect version that arrives a day too late [1]. In contrast, an 
evidence synthesis of poor quality and insufficiently rigorous is useless or even harmful. We 
need to rethink our expectations regarding the synthesis of evidence by considering a 
synthesis as a product in a process of continuous extension and improvement (allowing us to 
have the best possible synthesis at all times) rather than a finished product valid at a single 
time. The extent of thoroughness required to address a given question may vary from one 
topic to another and the “one size fits all” approach is not the best option.  
1.4 Tailoring the end-products of evidence synthesis to stakeholder needs 
The end users of evidence syntheses are multiple and have different needs that must be taken 
into account when designing and developing the products derived from evidence syntheses. 
These products could have varying format and sizes, different focus of content, and different 
language complexity and could be translated into different languages. Beyond the full review 
that must be as detailed as possible for researchers, different versions of the synthesis report 
could be prepared for the public, physicians, policymakers and others [7]. As an example, 
rapid reviews (i.e. a type of knowledge synthesis for which the steps of the systematic review 
are streamlined or accelerated to produce evidence in a shortened timeframe) have been 
proposed as an approach to provide actionable evidence in a timely manner for 
policymakers[7]. The co-creation process would help in producing such tailored outputs. 
1.5 Recognizing the importance of research on evidence synthesis 
A culture shift in the community (research funders, research institutions, journalists etc.) is 
needed to recognize that evidence synthesis is intellectually challenging and must be 
considered a respected activity that needs to be funded and rewarded like any research activity 
[1]. Indeed as an example, the NLM classifies systematic reviews and research articles 
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differently. Furthermore, systematic reviews are rarely highlighted by journalists despite the 
higher level of evidence. The recognition is currently geographically inconsistent [4]. 
Furthermore, research on evidence synthesis methods must be recognized as an important 
field of research considering the permanent need to develop and validate innovative and 
complex methods to respond to the emergence of new data sources and data types as well as 
the evolution of needs and expectations of end users.  
2 DEVELOPING A HARMONIZED INTERNATIONAL WORK PLAN 
Moving toward the new evidence synthesis ecosystem and encouraging communities to work 
together continuously will require greater incentives and rewards for all stakeholders. To 
achieve this goal, mechanisms of funding, the research evaluation framework and the 
dissemination practices of evidence syntheses need to be better aligned. 
 
2.1 Selecting priority topics and distributing workload globally  
The huge amount of work requires a distribution of the workload at the international level. 
Multiple teams all over the world are dedicating time and resources to produce evidence 
syntheses, which are overlapping and redundant. We need to collectively rethink the needs of 
evidence community and create a marketplace for evidence synthesis in which all 
stakeholders will find the evidence they need on a specific topic. The evidence synthesis 
ecosystem must be organized at a global level with a geographically widespread reach rather 
than geographically localized distribution of work.  
Because all topics of interest cannot be covered, priorities should be defined. The 
criteria for defining these priorities could be related to the burden of disease and topics for 
which the pace of evidence change is the fastest. For each relevant clinical question 
considered a priority topic by the network of evidence synthesis stakeholders, one living 
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evidence synthesis community needs to be set up to perform the initial evidence synthesis and 
keep it up to date.  
Furthermore, at one point, the research question may not be relevant anymore, and 
consequently the living systematic review should be stopped. In other situations, the living 
systematic review could become an open-ended activity. Hence, communities must have a 
process to determine when the living systematic review should be closed. 
 
2.2 Setting up living evidence synthesis communities 
Groups of researchers, health professionals, guidelines developers, policymakers, patients or 
their representatives and methodologists interested in a particular theme could take the lead 
for a given topic. These living groups will commit to ensuring the long-lived rather than 
ephemeral maintenance of the evidence synthesis on this topic, thereby creating a unique 
marketplace for this topic in which all stakeholders will find the current best evidence. The 
community could encourage deep engagement (and in particular that of end-users) to 
exchange perspectives and understand priorities and help create a positive climate of 
collaboration. This community will be in charge of performing the initial evidence synthesis 
for the question of interest and keeping the synthesis up-to-date over time. This initial 
evidence synthesis should be a Network Meta-Analysis (NMA), namely a technique for 
comparing three or more interventions simultaneously in a single analysis by combining both 
direct and indirect evidence across a network of studies. A different approach from a one-off 
publication in a prestigious journal is needed for publishing such reviews, such as an online 
community with alerts for practice-changing updates. 
To ensure both the diversity of viewpoints and the dissemination of results, involving people 
from different countries, specialties and cultures is especially important. The living evidence 
synthesis community would consist of different open embedded groups, in which contributors 
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can move in and out but share common research principles, scientific goals and 
methodological approaches. The different groups can have different backgrounds and skills 
(e.g., anyone interested in the disease, including patients or their representatives, clinicians, 
trialists, methodological experts) and so will have different specific tasks in the evidence 
synthesis process [8]. These communities will share the same values, methods and principles 
(e.g., for conflicts of interests) but would be allowed to adapt their methods and objectives to 
their topic of interest and to the needs of stakeholders in their specific area. Particular 
attention and specific safeguards should be in place to avoid the undue influence of lobby 
bodies such as the pharmaceutical industry. The role of each community member and their 
conflict of interest should be completely transparent. As an example, the need for using 
observational data in evidence synthesis may be different in domains for which few 
randomized controlled trials exist (e.g., surgery) as compared with domains for which 
multiple randomized controlled trials are available. Furthermore, the benefits of incorporating 
real-world data must be systematically considered. We have already described an example of 
such a community in paper 2 (section 2.2. Living network meta-analyses, and Figure 1). 
Some initiatives such as the SPOR Evidence Alliance, a Canada-wide alliance of researchers, 
research trainees, patients, healthcare providers, policy makers and organizations who use 
research to inform decisions, would help to build capacity for such communities.  The SPOR 
Capacity Development Framework offer multidisciplinary mentorship opportunities in 
knowledge synthesis and knowledge translation and has the goal to build a culture of 
interdisciplinary collaboration [9]. 
2.3 Reinventing a new reward system for living evidence synthesis 
Evidence syntheses must be quickly discarded once outdated [1]. An open-access repository 
in which all living evidence syntheses produced collectively can be saved, shared, updated 
over time and retrieved by each stakeholder seems the best option for wide dissemination and 
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ensuring timely updates. The aggregated data extracted could also be shared to allow for data 
verification or re-analysis by the research community. However, the current reward system, 
mainly based on publication in peer-reviewed journals, is challenged because no publications 
per se are needed in this new system. The currently prevailing reward system could be a major 
barrier particularly for young contributors. Requesting digital object identifiers for the 
analysis results and data could be a solution [10]. We could also consider that a publication in 
peer-reviewed journals is necessary when evidence on benefits/harms changes, or we could 
propose to regularly publish a document of the state-of-the-art of available evidence for the 
clinical question of interest. 
The usual peer-review process will also be challenged by such an approach because it 
would considerably delay access to information, which will not be acceptable. Alternative 
forms of publication (e.g., preprint publication) or peer-review (e.g., post-publication peer-
review) need to be considered to allow rapid access to the information. 
A collaborative reflection exercise is needed to refine the current reward system and 
properly reward researchers commensurate with their contribution over time.  
 
2.4 Future role of organizations such as Cochrane 
International organizations are the best placed to govern, organize and implement such a 
fundamental change to the system. The main features expected for these organizations are 
credibility, broad international presence, independence from the main lobby bodies, and 
interest in evidence building. Such organizations will have to the identify enduring questions 
and their allocation globally. 
Cochrane has the historical legitimacy, a network of trained members and volunteer 
contributors, and the organizational capacity. Cochrane has demonstrated its capacity to scale 
evidence synthesis in health and to involve a large number of volunteers, train its volunteers, 
and develop and make use of the same methods by all, to ensure that the level of quality is 
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consistent despite the diversity of topics and contributors. Cochrane could have a potential 
future role in prioritization, setting up teams, hosting evidence syntheses, methodological 
developments, and advocacy. However, Cochrane would have to go far beyond its comfort 
zone (i.e., evidence synthesis) to take the lead in this area (primary evidence and evidence 
synthesis). In the same spirit, the Joanna Briggs Collaboration, involving 70 Collaborating 
Entities across 34 countries, contribute to improve in the quality of healthcare globally 
through the delivery of high quality programs of evidence synthesis for end users, including 
transfer and implementation [11].  
Such organizations could act as important facilitators and essential partners with any new or 
existing or network of organizations (e.g., The International Network of Agencies for Health 
Technology Assessment) wishing to take the lead.  
 
2.5 Optimizing resources by involving agencies for health technology 
assessment 
Many actors involved in evidence synthesis (researchers, Cochrane members, Health 
Technology Agency staff, guideline developers) perform systematic reviews and meta-
analyses in an uncoordinated manner, frequently without knowing that another team in the 
world is doing the same work. These syntheses are often redundant, and even if their 
objectives and methods may be slightly different, their overall aims and processes are very 
similar. Independent duplication of efforts to solve questions may be useful. However, 
replication/duplication is much more likely to be useful if it is an informed and reasoned 
choice. Coordinating these efforts would help avoid duplicate or overlapping systematic 
reviews. It would also help to dedicate more resources for research that at least part of the 
scientific community considered collegially as useful and important, thereby allowing for 
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faster and more efficient reviews. Furthermore, involving both systematic reviewers and the 
potential targeted audience throughout the process of evidence synthesis in designing the 
question, governing the process and interpreting the findings should help improving the 
relevance of reviews for decision-makers. Funding sustainable infrastructures in charge of 
such ecosystems rather funding short projects might also ensure that it is not a one-shot 
initiative. 
 
3 MOVING FROM AN EVIDENCE SYNTHESIS ECOSYSTEM TO AN EVIDENCE 
ECOSYSTEM  
Evidence synthesis requires brokerage at the interface of public life and academia. Improving 
collaboration will bring academics, policymakers, practitioners, funders and publishers closer 
to a world in which decision-making can be built on solid ground [1]. Currently, primary 
research, evidence synthesis and guidelines development and adoption of evidence into 
clinical practice are largely siloed. However, they are interdependent, and any improvement in 
one component of the system will benefit the whole system. A natural objective would be to 
bring the different communities together for their mutual benefit. As an example, we could 
assume that collecting data on the transparency of trials during a systematic review and 
disclosing these data will eventually improve the transparency of primary research and 
therefore the quality of subsequent systematic reviews. In the same way, developing living 
meta-analyses will help accelerate the production of up-to-date guidelines. The living 
evidence synthesis communities would be extended to living evidence communities involved 
in evidence synthesis and also in primary evidence generation and evidence translation to 
guidelines. This development would be conceived in the context of the broader system with 




3.1 Creating feedback loops between living evidence synthesis and primary 
research communities  
Reinforcing the link between trialists and systematic reviewers is a major objective to 
implement a virtuous circle of continuous improvement in the quality of evidence, 
improvement in primary research and therefore improvement in the quality of future evidence 
synthesis. Moreover, highlighting the unsolved clinical questions gives pointers to scientists, 
policymakers and funders on potential lines of enquiry to fill knowledge gaps [12]. 
- Living monitoring of methodological quality of trials 
Asking systematic reviewers to collect a limited number of additional data when they are 
performing their review should be doable. The incremental cost of collecting additional data 
at this stage represents a limited and manageable effort with significant potential long-term 
benefits.  
Some of the data necessary for monitoring the methodological quality of trials are 
already extracted for most reviews (e.g., items to assess the Cochrane Risk of Bias tool 
[RoB]). For example, systematic reviewers could check whether a Core Outcome Set is 
proposed for the disease and recorded in the trial report or could identify major 
methodological issues.   
Providing access to this information will help trialists improve the planning of their future 
trial by avoiding reproducing some methodological errors or forgetting essential outcomes 
and therefore decrease the waste in future research. In fact, we are convinced that no trialist 
would be satisfied with planning a trial that will later be considered at high risk of bias or that 
could not be included in evidence synthesis because outcomes were not recorded and that they 
would modify their design if they were aware of it before the trial began.  
- Living monitoring of transparent reporting of trials  
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In the same way, we could perform a living monitoring of the transparent and complete 
reporting of trials by assessing the quality of reporting for the most important items. We could 
perform a permanent audit of the rate of publications and posting of trials, their compliance 
with the 2007 US Food and Drug Administration Amendments Act (FDAAA) that requires 
sponsors of trials in the United States to post results on ClinicalTrials.gov and the European 
Union requirement to post results on the European Clinical Trials Database (EudraCT). 
Furthermore, we could use the RoB assessment as a marker of the completeness of 
reporting. Indeed, with the new version of the RoB tool (RoB 2.0), all signaling questions 
rated by systematic reviewers as “No information” are considered poorly reported. The 
evaluation of the completeness of reporting and the extraction of results as soon as a trial is 
published could be performed systematically. An immediate contact with investigators could 
clarify the reporting. Investigators contacted immediately after the trial is published would 
probably be more likely to clarify the information as opposed to several years after the end of 
the trial when a systematic review is performed. Finally, it would be useful to ask the 
investigators of each trial if they would give access to the protocol of their trial or if they 
would agree to share their data and under which conditions.  
- Living reporting system of the quality, transparency and accessibility of data 
All these data would then be used for a living disclosure of the quality and transparency of 
reporting. The mapping and disclosure by medical specialties, journals, funders or universities 
of research transparency would likely have a positive effect on various stakeholders and 
would help raise awareness about the waste related to poor reporting, thereby motivating 
actors to develop quality improvement programs. In the same way, a mapping of the 
stakeholders who make their data publicly available would be useful [13].  
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We can also have a more proactive and incentive approach to improve transparency by 
identifying on ClinicalTrials.gov and EudraCT all trials as soon as they are terminated and 
systematically encouraging principal investigators via automatically generated emails to post 
their results on registries within 1 year after the end of the trial. This approach has already 
demonstrated its impact in a randomized trial [14]. We could also encourage investigators to 
give access to their protocols, publish their results and archive their data and direct them to 
practical repository solutions to share their data if needed.   
- Living mapping of research 
Having a global view of the research already carried out or in progress (and its state of 
advancement) is crucial for researchers who will plan a research project, funders who will 
decide whether or not to fund new research and institutional review boards who will assess its 
ethical nature. Accessing this information is not straightforward because the data needed to 
perform this mapping are scattered, and creating a global observatory for health research and 
development has been advocated [15]. Living mapping of evidence for one specific topic of 
interest can be built to represent both current (all existing trials) and also ongoing evidence 
(all ongoing trials). This mapping would improve the coordination of clinical research by 
helping trialists plan their future trial and choose the most relevant comparator and 
inclusion/exclusion criteria as well as guide the allocation of public resources by funders. 
Funders might also think more imaginatively by funding research ecosystems around a 
prioritized topic rather than separate evidence syntheses and primary research. Such a 
research “programme” is likely to require more funds than the small amounts available for 
answering specific isolated questions, and many funders’ budgets will simply not cover all 
conditions in this way. Nevertheless, such a joined-up system of funded evidence syntheses, 
platform trials [16] that can quickly add a new drug, or a comparison identified in an NMA, 
and a living guidelines group and clinical research community could be a very powerful and 
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efficient way for conducting research rather than the piecemeal and “stop/start” culture than 
currently prevails. 
- Living individual participant data network meta-analysis  
For some specific and well-chosen questions (i.e., when the additional work is justified by its 
benefit to the end user), the ultimate goal would be to access individual participant data (IPD) 
rather than aggregated data and to perform living individual participant data NMA. IPD data 
are considered the gold standard for evaluating the intervention effects in pairwise meta-
analysis and NMA because they allow for properly evaluating assumptions and handling the 
potential for bias from several sources; furthermore, they would allow for assessing the effect 
of interventions in subgroups of patients. This goal, which seemed completely unrealistic and 
unattainable only a few years ago, now seems more likely to be achievable, even within a few 
years. The lack of data sharing is recognized as a waste in research and is becoming 
increasingly politically inappropriate. Several organizations, funders and pharmaceutical 
companies have been brought together in an effort to support large-scale data sharing, and this 
is expected to boost the availability of IPD data in the wider research community.  
 
3.2 Bridging the gaps between evidence synthesis communities, clinical practice 
guidelines developers, agencies for health technology assessment, health policy 
authorities and primary researchers 
A new evidence ecosystem should allow for bridging the gap between not only systematic 
reviewers and trialists but also with developers of clinical practice guidelines.  
Living NMA provides a network of current evidence for the clinical question of 
interest representing all treatments assessed and trials performed in this setting. It offers 
constant access to updated global evidence synthesis and may help improve real-time 
knowledge transfer from systematic reviews and meta-analyses to clinical practice guidelines. 
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This living NMA repository would be the marketplace for evidence synthesis, whereby 
groups of guideline developers will find the best evidence and access to the data that were 
extracted. They could re-use these data, reanalyse all or some of these data, add other data and 
thus produce locally relevant and applicable guidelines. For example, they could decide to 
consider only data of trials performed in relevant settings according to their geographic area. 
The ultimate goal will be to reach the step of implementing “living clinical practice 
guidelines” [17–19].  
Currently, only a small number of clinical guidelines are based on a high certainty of 
evidence [20–24] as mentioned in paper 2. Therefore, we need to bridge the gaps between 
guidelines developers and primary researchers. Implementing living NMA and living clinical 
practice guidelines will help in outlining what is not known, will allow for assessing the 
trustworthiness of the evidence underlying each recommendation and will therefore help the 
research community streamline future clinical trials and focus on areas of deficient evidence 
to expand the evidence base from which clinical practice guidelines are derived.  
3.3 Create links between living evidence synthesis communities and decision-makers 
The creation of a partnership with decision-makers, such as guidelines developers, regulators 
and governments, will help support, promote and sustain the paradigmatic and cultural shift to 
living evidence synthesis for each priority topic selected [25]. All stakeholders, including 
decision-makers, should be involved throughout the whole process.  
 
3.4 Moving toward a global learning health system  
From a broader perspective, we need to set up a global learning health system with positive 
feedback loops in real time to improve the global system of evidence production. For each 
topic or question of interest, a community can be constituted and a learning system developed. 
All these systems contribute to the overall learning system. Cochrane seems naturally in an 
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excellent position to coordinate this learning system. However, some activities of such living 
evidence communities would require Cochrane to step far outside its current scope, agree to 
extend its field of action and accept a fundamental change in its activity and organization. 
This move would imply profound questioning and changes to remain innovative, competitive 
and attractive in an expanding marketplace of evidence.  
Figure 1 summarizes the idea of a continuous improvement of clinical research and Box 1 the 
different steps to facilitate the implementation of this new evidence ecosystem. 
 
CONCLUSION  
Despite the multiple challenges, the network of evidence stakeholders must bring their longer-
horizon efforts in line with the pragmatic questions of importance to patients, physicians and 
decision-makers. This new approach may offer an innovative solution to the current problems 
with and the imperative need to provide up-to-date evidence synthesis of all available 
treatments for a specific clinical question. 
Reinventing the global system of producing evidence needs to overcome the scientific, 
technical and logistical challenges and the constraints of the current scientific system. 
A better evidence ecosystem will require collaborations and interactions between each 
partner of the network of evidence synthesis stakeholders. Links between the living evidence 
synthesis community and agencies for health technology assessment, health policy authorities, 
primary researchers and clinical practice guidelines developers with facilitation by the 
Cochrane collaboration should allow for living evidence syntheses according to the high 
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Box 1. Different steps to facilitate the implementation of this new evidence ecosystem  
 
 
To create a living community dedicated to one condition 
• The community shall gather clinicians, systematic reviewers, patients, trialists, methodologists, 
statisticians and guidelines experts willing to join their efforts to improve the production of evidence in a 
specific field  
• The community should define specific safeguards to avoid the undue influence of lobbies such as 
pharmaceutical industry. The role of each community member and their conflict of interest should 
completely transparent. 
• The community should agree on  
- The research questions to be explored in priority 
- The sources of data to be used 
- The types of data (randomized trials, observational data, individual-patient data) to consider 
• The community should distribute the work to diverse teams disseminated worldwide 
• The community should agree on a new reward system to properly reward researchers commensurate with 
their contribution over time  
 
To set-up a living mapping of research (ongoing and completed research) and a living network meta-
analysis of all available treatments, continuously updated for a specific condition or therapeutic indication to  
• Perform the initial evidence synthesis (initial network meta-analysis) 
• Organize updates at a pace adapted to their topic and the speed of knowledge production 
• Organize the knowledge transfer toward the various stakeholders 
- To tailor the end-products to stakeholders needs and develop a different version for each 
stakeholder. For example, the end product for trialist could be tools to help guide the sample size 
calculation, chose the outcomes measurements, chose the comparator, set up eligibility criteria, 
chose centers etc.  
- To provide access to the most updated results and to the data immediately on an open platform 
- To publish results when relevant 
 
To organize the living monitoring and feedback to all stakeholders (funders, trialists, journal editors, 
institutions etc.) of trials quality and transparency 
• The living monitoring of trials conducting quality will consist of assessing and reporting whether 
- Outcomes used are consistent and in line with the core outcomes set 
- The trials identified are at high risk of bias according to the risk of bias tool, why and how 
methodological errors identified could be avoided. 
- Patients are involved in the study design 
• The living monitoring of trials transparency and completeness of reporting will consist of assessing and 
reporting whether 
- Trials protocols are available 
- Trials data are archived and where 
- Trials results are available (e.g., posted or published) 
- Trials are completely reported 
- Individual-patient data are accessible and under what conditions 
• The feedback could consist of  
- A living disclosure of trials quality and transparency  
- A tailored feedback to specific stakeholders (funders, institutions, journal editors) 
- Reminders for posting trial results on registries 
- Tailored guidance for data reporting and data sharing 
 
To organize the process for the development of living guidelines  
- Giving access to the data that were extracted to guidelines developers who could re-use these data, 
reanalyse all or some of these data, add other data and thus produce locally relevant and applicable 
guidelines. 
 
 
 
